The Fabulous Neuroprotection of Selegiline: Memoir and Prospectus

Abstract

Get full access to this article

View all access options for this article.

References

Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol. 1989;46: 1052-1060.

Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med . 1989;321: 1364-1371.

Landau WM Clinical neuromythology IX: pyramid sale in the bucket shop: DATATOP bottoms out. Neurology. 1990;40: 1337-1339.

Klawans H. Chekhov’s Lie. New York: Demos Vermande; 1997:101-102; 165-167; 211; 217-218.

Landau WM Special correspondence. DATATOP and clinical neuromythology IX. Neurology. 1991;41:771-777.

Daroff RB Correspondence to the editor: neuromythology IX and DATATOP. Neurology. 1991;41:1703-1704.

Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease: DATATOP subjects not requiring levodopa. Ann Neurol. 1996;39:29-36.

Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects requiring levodopa. Ann Neurol. 1996;39:37-45.

Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson’s disease. Ann Neurol. 1998;43:318-325.

10.

Lees AJ (Parkinson Disease Research Group of the United Kingdom). Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. BMJ. 1995;311: 1602-1607.

11.

Mann JJ , Aarons SF , Wilner PJ , et al. A controlled study of the antidepressant efficacy and side effects of deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry. 1989;46: 45-50.

12.

Pålhagen S. , Heinonen EH , Häglund J. , et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology. 1998;51:520-525.

13.

Shoulson I. and the Parkinson Study Group. DATATOP: a decade of neuroprotective inquiry. Ann Neurol. 1998;44(Suppl 1): S160-S166.

14.

Shoulson I. , Oakes D. , Fahn S. , et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002;51:604-612.

15.

Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498-2508.

16.

Suchowersky O. , Gronseth G. , Perlmutter J. , et al. Practice parameter, neuroprotective strategies and alternative therapies for Parkinson disease, an evidence-based review: report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2006;66:976-982.

17.

Schapira AH , Obeso J. Timing of treatment initiation in Parkinson’s disease: a need for reappraisal? Ann Neurol. 2006; 59:559-565.

18.

Parkinson Study Group PRECEPT investigators. Mixed lineage kinase inhibitor CEP1347 fails to delay disability in early Parkinson disease. Neurology. 2007;69:1480-1490.

19.

PDR Network, LLC. Physician’s Desk Reference. 64th ed. Montvale, NJ: PDR Network, LLC; 2010:3383-3388.

20.

Olanow CW , Rascol O. , Hauser R. , et al. for the ADAGIO Study Investigators: a double-blind, delayed-start trial of rasagiline in Parkinson’s Disease. N Engl J Med. 2009;361:1268-1278.

21.

Dorsey ER , Thompson JP , Dayoub EJ , et al. Selegiline shortage: causes and costs of a generic drug shortage . Neurology. 2009;73: 213-217.

22.

PDR Network, LLC. Physician’s Desk Reference. 64th ed. Montvale, NJ: PDR Network, LLC. 2010:3312.

23.

Ahlskog JE Beating a dead horse: dopamine and Parkinson disease. Neurology . 2007;69:1701-1711.

24.

Shannon KM Dopamine: so ‘‘last century.’’ Neurology . 2007;69: 329-330.

25.

Voss T. , Ravina B. Neuroprotection in Parkinson’s disease: myth or reality? Curr Neurol Neurosci Rep. 2008;8:304-309.

26.

Marras C. , Lang A. Changing concepts in Parkinson disease: moving beyond the decade of the brain . Neurology. 2008;70: 1996-2003.